Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  stage III renal cell cancer
Trial Type:  Treatment
Results 1-25 of 64 for your search:
Start Over
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CA209-374, NCI-2016-00405, 2015-003286-28, NCT02596035
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991003, NCI-2016-00392, 2015-002429-20, JAVELIN RENAL 101, NCT02684006
Stereotactic Radiosurgery in Treating Patients with Kidney Tumors Who Are Poor Candidates for Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201303150, NCI-2013-00641, NCT01784861
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Vandetanib and Metformin Hydrochloride in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0157, NCI-2015-01978, P152144, NCT02495103
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMBG453X2101, NCI-2015-02091, 2015-002354-12, NCT02608268
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCA, NCI-2016-00531, NCT02667886
Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CX-839-004, NCI-2016-00900, NCT02771626
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Pazopanib Hydrochloride or Temsirolimus in Treating Patients with Metastatic or Locally Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Capmatinib in Treating Patients with Papillary Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0037, NCI-2014-02464, 09-25-0099, 140037, 340263, P131324, NCT02019693
Stereotactic Body Radiation Therapy Compared to Radiofrequency Ablation in Treating Patients with Localized Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.069, NCI-2014-01216, 2013.069, HUM00076618, NCT02138578
Stereotactic Ablative Body Radiation Therapy in Treating Patients with Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 122013-030, NCI-2014-02122, NCT02141919
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RXDX-101-02, NCI-2015-01848, NCT02568267
Everolimus in Treating Patients with Birt Hogg Dubé Syndrome or Locally Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0166, NCI-2015-01979, P152218, NCT02504892
Personalized Dose of Axitinib in Treating Patients with Previously Treated Local Recurrent or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE7815, NCI-2016-00020, 15-1386, IRB# 15-1386, NCT02579811
Start Over